Lupin resumes sales of Generic Fortamet

19 Apr 2012 Evaluate

Pharma Major, Lupin has been granted its request to stay the preliminary injunction by the US Court of Appeals for the Federal Circuit that had earlier barred sales of its generic of Shionogi’s Fortamet tablets. Lupin’s Metformin Hydrochloride tablets are the AB-rated generic equivalent of Fortamet 500 mg and 1000 mg tablets. The company has resumed sales of its product.

Lupin had earlier received final approval for its Metformin tablets from the US FDA and had launched the product in September, 2011. In December, 2011 Shionogi’s request for a preliminary injunction had been granted and had blocked Lupin from further sales of the product.

Fortamet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The annual US sales for Fortamet stood at $70.2 million for the twelve months ending December 2011, as per IMS Health data.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2100.00 -12.95 (-0.61%)
29-Dec-2025 10:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.90
Dr. Reddys Lab 1265.50
Cipla 1503.95
Zydus Lifesciences 905.95
Lupin 2100.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×